Mariateresa Buongiorno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mariateresa Buongiorno has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Gonzalo Sánchez-Benavides
Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain
6 shared publications - Darly Milena Giraldo
Neurology Department, Vall d’Hebron University Hospital, 08035 Barcelona, Spain
5 shared publications - Jerzy Krupinski
Department of Neurology, Mútua Terrassa University Hospital, 08221 Barcelona, Spain
5 shared publications - Natalia Cullell
Fundació per a Docència I Recerca, MútuaTerrassa, 08221 Terrassa, Spain
5 shared publications - Giovanni Caruana
Department of Neurology, Fundació Assistencial Mútua Terrassa, 08221 Terrassa, Spain
4 shared publications Gonzalo Sánchez-Benavides
Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain
4 shared publications
Latest Publications
- 11 February 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (3) , 249
Characterization of neuropsychiatric symptoms in patients with early-stage Alzheimer’s disease in a specialized outpatient clinic
Objective To describe the frequency and temporal onset of neuropsychiatric symptoms (NPS) around the diagnosis of Alzheimer’s disease (AD) and to explore their associations with clinical and paraclinical variables. Methods We conducted a retrospective observational study of patients diagnosed with AD between 2020 and 2024, including NPS emerging from six years before to four years after diagnosis. Symptoms were classified by temporal onset as preNPS or postNPS and categorized into affective, psychotic, and behavioral domains. Clinical and demographic data, cerebrospinal fluid (CSF) biomarkers, and FDG-PET imaging findings were collected. Results Among 184 patients (mean age 76.7 ± 9.0 years; 68% female), preNPS occurred in 78.2% and postNPS in 53.8%. Psychotic preNPS were associated with older age (81.4 ± 8.6 vs. 76.3 ± 8.9 years; p = 0.049), lower Mini-Mental State Examination scores (19.9 ± 3.7 vs. 22.1 ± 4.1; p = 0.033), and use of benzodiazepines (38.5% vs. 14.0%; p = 0.036) and antipsychotics (61.5% vs. 7.0%; p < 0.001). Affective preNPS were more common in women (71.9% vs. 55.4%; p = 0.029) and were associated with antidepressant use (p < 0.001) and lower alcohol intake (p = 0.018). Behavioral preNPS predominated in men (57.1% vs. 30.1%; p = 0.013) and were associated with a greater preservation of temporal lobe metabolism in FDG-PET imaging (28.0% vs. 76.2%; p = 0.04). PostNPS correlated with disease duration (r = 0.19; p = 0.01) and higher CSF total tau levels (386.9 ± 112.8 vs. 347.1 ± 148.9; p = 0.04). Conclusion NPS are frequent in early-stage AD, with psychotic preNPS linked to older age and greater cognitive decline, and postNPS correlating with disease duration and CSF tau, indicating an association with neurodegeneration.
- 11 February 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (3) , 249
Characterization of neuropsychiatric symptoms in patients with early-stage Alzheimer’s disease in a specialized outpatient clinic
Objective To describe the frequency and temporal onset of neuropsychiatric symptoms (NPS) around the diagnosis of Alzheimer’s disease (AD) and to explore their associations with clinical and paraclinical variables. Methods We conducted a retrospective observational study of patients diagnosed with AD between 2020 and 2024, including NPS emerging from six years before to four years after diagnosis. Symptoms were classified by temporal onset as preNPS or postNPS and categorized into affective, psychotic, and behavioral domains. Clinical and demographic data, cerebrospinal fluid (CSF) biomarkers, and FDG-PET imaging findings were collected. Results Among 184 patients (mean age 76.7 ± 9.0 years; 68% female), preNPS occurred in 78.2% and postNPS in 53.8%. Psychotic preNPS were associated with older age (81.4 ± 8.6 vs. 76.3 ± 8.9 years; p = 0.049), lower Mini-Mental State Examination scores (19.9 ± 3.7 vs. 22.1 ± 4.1; p = 0.033), and use of benzodiazepines (38.5% vs. 14.0%; p = 0.036) and antipsychotics (61.5% vs. 7.0%; p < 0.001). Affective preNPS were more common in women (71.9% vs. 55.4%; p = 0.029) and were associated with antidepressant use (p < 0.001) and lower alcohol intake (p = 0.018). Behavioral preNPS predominated in men (57.1% vs. 30.1%; p = 0.013) and were associated with a greater preservation of temporal lobe metabolism in FDG-PET imaging (28.0% vs. 76.2%; p = 0.04). PostNPS correlated with disease duration (r = 0.19; p = 0.01) and higher CSF total tau levels (386.9 ± 112.8 vs. 347.1 ± 148.9; p = 0.04). Conclusion NPS are frequent in early-stage AD, with psychotic preNPS linked to older age and greater cognitive decline, and postNPS correlating with disease duration and CSF tau, indicating an association with neurodegeneration.
- Open Access
Aquaporin-4 polymorphisms modify the penetrance of Parkinson’s disease in leucine-rich repeat kinase 2 carriers
Background: Pathogenic mutations in the leucine-rich repeat kinase-2 ( LRRK2 ) gene are the most common cause of familial Parkinson’s disease (PD). LRRK2 shows incomplete penetrance, yet the biological factors influencing disease expression remain unknown. Objectives: To investigate whether genetic variants in aquaporin-4 ( AQP4 ), key in glymphatic system functioning, are associated with the penetrance of PD in LRRK2 carriers. Methods: We analyzed baseline data from 302 LRRK2 carriers from the Parkinson’s Progression Markers Initiative. Fourteen AQP4 single nucleotide polymorphisms, previously implicated in PD, Alzheimer’s disease, or other neurodegenerative-related processes were tested for association with PD manifestation using logistic regression models adjusted for age and sex. Recessive, dominant, and additive genetic models were explored. Sensitivity analyses were conducted in G2019S carriers (n=273). Results: One hundred twenty-seven (42%) LRRK2 carriers were asymptomatic, and 174 (58%) had PD. There were no differences between groups in age (63.5[9.5] vs. 62.2[7.5]) or number of women (52.0% vs. 55.7%). Homozygosity for the minor allele of rs9951307 was associated with reduced likelihood of PD (OR=0.28, 95% CI 0.10–0.64, p=0.005), whereas rs335930 homozygosity was associated with increased likelihood (OR=4.2, 95% CI 1.41–15.6, p=0.016). Additive models supported these associations, though rs335930 did not surpass the adjusted threshold. Results were consistent in the G2019S subgroup. Conclusions: AQP4 polymorphisms may contribute to the variable penetrance of LRRK 2 mutations, potentially though modulation of glymphatic clearance. These findings support the glymphatic system as a relevant pathway in familial PD and highlight AQP4 as a candidate therapeutic target.
Open AccessAquaporin-4 polymorphisms modify the penetrance of Parkinson’s disease in leucine-rich repeat kinase 2 carriers
Background: Pathogenic mutations in the leucine-rich repeat kinase-2 ( LRRK2 ) gene are the most common cause of familial Parkinson’s disease (PD). LRRK2 shows incomplete penetrance, yet the biological factors influencing disease expression remain unknown. Objectives: To investigate whether genetic variants in aquaporin-4 ( AQP4 ), key in glymphatic system functioning, are associated with the penetrance of PD in LRRK2 carriers. Methods: We analyzed baseline data from 302 LRRK2 carriers from the Parkinson’s Progression Markers Initiative. Fourteen AQP4 single nucleotide polymorphisms, previously implicated in PD, Alzheimer’s disease, or other neurodegenerative-related processes were tested for association with PD manifestation using logistic regression models adjusted for age and sex. Recessive, dominant, and additive genetic models were explored. Sensitivity analyses were conducted in G2019S carriers (n=273). Results: One hundred twenty-seven (42%) LRRK2 carriers were asymptomatic, and 174 (58%) had PD. There were no differences between groups in age (63.5[9.5] vs. 62.2[7.5]) or number of women (52.0% vs. 55.7%). Homozygosity for the minor allele of rs9951307 was associated with reduced likelihood of PD (OR=0.28, 95% CI 0.10–0.64, p=0.005), whereas rs335930 homozygosity was associated with increased likelihood (OR=4.2, 95% CI 1.41–15.6, p=0.016). Additive models supported these associations, though rs335930 did not surpass the adjusted threshold. Results were consistent in the G2019S subgroup. Conclusions: AQP4 polymorphisms may contribute to the variable penetrance of LRRK 2 mutations, potentially though modulation of glymphatic clearance. These findings support the glymphatic system as a relevant pathway in familial PD and highlight AQP4 as a candidate therapeutic target.
- Open Access
- 11 September 2025
- Published by MDPI AG in Neurology International
- Vol. 17 (9) , 147
A Pilot Study: The Effect of CPAP Intervention on Sleep Architecture and Cognition in Alzheimer’s Disease Patients with Obstructive Sleep Apnea
Background: Obstructive sleep apnea (OSA) is highly prevalent in the early stages of Alzheimer’s disease (AD), and its hallmark, sleep fragmentation, may accelerate cognitive decline. Continuous positive airway pressure (CPAP) improves OSA-related hypoxia during slow-wave sleep, but its cognitive benefits in AD remain unclear. Methods: We performed a 12-month sub-analysis of a prospective, longitudinal pilot study that enrolled 21 adults (median age = 77 yr; 71% women) with Mild Cognitive Impairment (MCI) with AD confirmed biomarkers and polysomnography-diagnosed OSA. All participants underwent baseline overnight polysomnography (PSG) and neuropsychological testing (Clinical Dementia Rating (CDR), Mini-Mental State Examination (MMSE), Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)) that were repeated after 12 months. Twelve participants were CPAP-compliant (moderate/severe OSA) and nine were non-users (mild OSA/intolerance). Cognitive change scores (Δ = 12 months -baseline) were compared with Generalized Linear Models (GLM) adjusted for baseline cognition and Apnea–Hypopnea Index (AHI); associations between baseline sleep parameters and cognitive trajectories were examined. And the association of sleep variables with the use of CPAP was also evaluated. Results: Compared with non-users, CPAP users showed significantly slower global decline (Δ MMSE: p = 0.016) and improvements in overall cognition (Δ RBANS Total: p = 0.028) and RBANS sub-domains (Δ RBANS FC: p = 0.010; Δ RBANS SF: p = 0.045). Longer baseline non-rapid eye movement (NREM) stage 3 and rapid eye movement (REM) sleep, greater total sleep time and sleep efficiency, and right-side sleeping were each linked to better cognitive outcomes, whereas extended NREM stage 2, wakefulness, and supine sleeping were associated with poorer trajectories. Conclusions: Twelve months of CPAP use was associated with attenuated cognitive decline and domain-specific gains in AD-related MCI with OSA. Sleep architecture and body position during sleep predicted cognitive outcomes, underscoring the therapeutic relevance of optimizing breathing and sleep quality. Larger, longer-term trials are warranted to confirm CPAP’s disease-modifying potential and to clarify the mechanistic role of sleep in AD progression.
- 11 September 2025
- Published by MDPI AG in Neurology International
- Vol. 17 (9) , 147
Open AccessA Pilot Study: The Effect of CPAP Intervention on Sleep Architecture and Cognition in Alzheimer’s Disease Patients with Obstructive Sleep Apnea
Background: Obstructive sleep apnea (OSA) is highly prevalent in the early stages of Alzheimer’s disease (AD), and its hallmark, sleep fragmentation, may accelerate cognitive decline. Continuous positive airway pressure (CPAP) improves OSA-related hypoxia during slow-wave sleep, but its cognitive benefits in AD remain unclear. Methods: We performed a 12-month sub-analysis of a prospective, longitudinal pilot study that enrolled 21 adults (median age = 77 yr; 71% women) with Mild Cognitive Impairment (MCI) with AD confirmed biomarkers and polysomnography-diagnosed OSA. All participants underwent baseline overnight polysomnography (PSG) and neuropsychological testing (Clinical Dementia Rating (CDR), Mini-Mental State Examination (MMSE), Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)) that were repeated after 12 months. Twelve participants were CPAP-compliant (moderate/severe OSA) and nine were non-users (mild OSA/intolerance). Cognitive change scores (Δ = 12 months -baseline) were compared with Generalized Linear Models (GLM) adjusted for baseline cognition and Apnea–Hypopnea Index (AHI); associations between baseline sleep parameters and cognitive trajectories were examined. And the association of sleep variables with the use of CPAP was also evaluated. Results: Compared with non-users, CPAP users showed significantly slower global decline (Δ MMSE: p = 0.016) and improvements in overall cognition (Δ RBANS Total: p = 0.028) and RBANS sub-domains (Δ RBANS FC: p = 0.010; Δ RBANS SF: p = 0.045). Longer baseline non-rapid eye movement (NREM) stage 3 and rapid eye movement (REM) sleep, greater total sleep time and sleep efficiency, and right-side sleeping were each linked to better cognitive outcomes, whereas extended NREM stage 2, wakefulness, and supine sleeping were associated with poorer trajectories. Conclusions: Twelve months of CPAP use was associated with attenuated cognitive decline and domain-specific gains in AD-related MCI with OSA. Sleep architecture and body position during sleep predicted cognitive outcomes, underscoring the therapeutic relevance of optimizing breathing and sleep quality. Larger, longer-term trials are warranted to confirm CPAP’s disease-modifying potential and to clarify the mechanistic role of sleep in AD progression.
- Open Access
- 29 August 2025
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 17, 1578270
Abnormal sleep blood pressure patterns are associated with the diffusion tensor imaging along the perivascular space index in cognitively impaired individuals
Introduction: Blood pressure (BP) physiologically dips during sleep, and a lack of dipping is associated with adverse health outcomes and cognitive decline. Vascular pulsatility is the primary driver of glymphatic cerebrospinal fluid (CSF) transport, which removes metabolic waste products from the brain during sleep. We hypothesized that abnormal sleep BP patterns may affect glymphatic system health and that this relationship may result in lower diffusion tensor imaging along the perivascular space (DTI-ALPS) indices, a proposed neuroimaging index of glymphatic health.Methods: A total of 21 participants with mild-to-moderate cognitive impairment underwent 24-h ambulatory BP monitoring (ABPM), DTI-MRI, and Alzheimer's disease (AD) biomarker assessments. Of them, eight participants were classified as dippers (≥10%) and 13 as non-dippers (< 10%), using the sleep/awake systolic BP (SBP) percentage of change.Results: We found that the non-dippers had lower DTI-ALPS indices, even after adjusting for age and clinical stage (p = 0.013). Stiffness measures (pulse wave velocity) were negatively correlated with DTI-ALPS (r = −0.5), but the association disappeared after adjusting for age. Positive AD biomarkers were more frequently observed in the individuals who were classified as non-dippers for both systolic and diastolic BP (DBP), compared to the systolic and diastolic dippers (p = 0.041).Discussion: Our findings suggest that deviations from the physiological BP dipping sleep pattern may be related to poorer glymphatic function and increased AD pathology.
- 29 August 2025
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 17, 1578270
Open AccessAbnormal sleep blood pressure patterns are associated with the diffusion tensor imaging along the perivascular space index in cognitively impaired individuals
Introduction: Blood pressure (BP) physiologically dips during sleep, and a lack of dipping is associated with adverse health outcomes and cognitive decline. Vascular pulsatility is the primary driver of glymphatic cerebrospinal fluid (CSF) transport, which removes metabolic waste products from the brain during sleep. We hypothesized that abnormal sleep BP patterns may affect glymphatic system health and that this relationship may result in lower diffusion tensor imaging along the perivascular space (DTI-ALPS) indices, a proposed neuroimaging index of glymphatic health.Methods: A total of 21 participants with mild-to-moderate cognitive impairment underwent 24-h ambulatory BP monitoring (ABPM), DTI-MRI, and Alzheimer's disease (AD) biomarker assessments. Of them, eight participants were classified as dippers (≥10%) and 13 as non-dippers (< 10%), using the sleep/awake systolic BP (SBP) percentage of change.Results: We found that the non-dippers had lower DTI-ALPS indices, even after adjusting for age and clinical stage (p = 0.013). Stiffness measures (pulse wave velocity) were negatively correlated with DTI-ALPS (r = −0.5), but the association disappeared after adjusting for age. Positive AD biomarkers were more frequently observed in the individuals who were classified as non-dippers for both systolic and diastolic BP (DBP), compared to the systolic and diastolic dippers (p = 0.041).Discussion: Our findings suggest that deviations from the physiological BP dipping sleep pattern may be related to poorer glymphatic function and increased AD pathology.
- Open Access
- 19 July 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (7) , 766
Sleep and Risk of Multiple Sclerosis: Bridging the Gap Between Inflammation and Neurodegeneration via Glymphatic Failure
Epidemiological studies identified insufficient and poor-quality sleep as independent risk factors for multiple sclerosis (MS). The glymphatic system, active during slow-wave sleep, clears brain waste through perivascular astrocytic aquaporin-4 (AQP4) channels. The presence of antigens induces a transient, physiological lowering of glymphatic flux as a first step of an inflammatory response. A possible hypothesis linking infection with the Epstein–Barr virus, a well identified causal step in MS, and the development of the disease is that mechanisms such as poor sleep or less functional AQP4 polymorphisms may sustain glymphatic flow reduction. Such chronic glymphatic reduction would trigger a vicious circle in which the persistence of antigens and an inflammatory response maintains glymphatic dysfunction. In addition, viral proteins that persist in demyelinated plaques can depolarize AQP4, further restricting waste elimination and sustaining local inflammation. This review examines the epidemiological evidence connecting sleep and MS risk, and the mechanistic findings showing how poor sleep and other glymphatic modulators heighten inflammatory signaling implicated in MS pathogenesis. Deepening knowledge of glymphatic functioning in MS could open new avenues for personalized prevention and therapy.
- 19 July 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (7) , 766
Open AccessSleep and Risk of Multiple Sclerosis: Bridging the Gap Between Inflammation and Neurodegeneration via Glymphatic Failure
Epidemiological studies identified insufficient and poor-quality sleep as independent risk factors for multiple sclerosis (MS). The glymphatic system, active during slow-wave sleep, clears brain waste through perivascular astrocytic aquaporin-4 (AQP4) channels. The presence of antigens induces a transient, physiological lowering of glymphatic flux as a first step of an inflammatory response. A possible hypothesis linking infection with the Epstein–Barr virus, a well identified causal step in MS, and the development of the disease is that mechanisms such as poor sleep or less functional AQP4 polymorphisms may sustain glymphatic flow reduction. Such chronic glymphatic reduction would trigger a vicious circle in which the persistence of antigens and an inflammatory response maintains glymphatic dysfunction. In addition, viral proteins that persist in demyelinated plaques can depolarize AQP4, further restricting waste elimination and sustaining local inflammation. This review examines the epidemiological evidence connecting sleep and MS risk, and the mechanistic findings showing how poor sleep and other glymphatic modulators heighten inflammatory signaling implicated in MS pathogenesis. Deepening knowledge of glymphatic functioning in MS could open new avenues for personalized prevention and therapy.
- Open Access
- 18 July 2025
- Published by MDPI AG in Preprints.org
The Effect of CPAP Intervention on Sleep Architecture and Cognition in Alzheimer’s Disease Patients with Obstructive Sleep Apnea
Background Obstructive sleep apnea (OSA) is highly prevalent in the early stages of Alzheimer’s disease (AD), and its hallmark, sleep fragmentation, may accelerate cognitive decline. Continuous positive airway pressure (CPAP) improves OSA-related hypoxia during slow-wave sleep, but its cognitive benefits in AD remain unclear. Methods We performed a 12-month sub-analysis of a prospective, longitudinal pilot study that enrolled 21 adults (median age = 77 yr; 71% women) with MCI with AD confirmed biomarkers and polysomnography-diagnosed OSA. All participants underwent baseline overnight PSG and neuropsychological testing (CDR, MMSE, RBANS) that were repeated after 12 months. Twelve participants were CPAP-compliant (moderate/severe OSA) and nine were non-users (mild OSA/intolerance). Cognitive change scores (Δ = 12 months – baseline) were compared with generalized linear models adjusted for baseline cognition and apnea-hypopnea index; associations between baseline sleep parameters and cognitive trajectories were examined. And the association of sleep variables with the use of CPAP was also evaluated. Results Compared with non-users, CPAP users showed significantly slower global decline (Δ MMSE: p = 1.60e-02) and improvements in overall cognition (Δ RBANS Total: p = 2.80e-02), and RBANS subdomains (Δ RBANS FC: p = 1.06e-02; Δ RBANS SF: p = 4.53e-02). Longer baseline NREM stage 3 and REM sleep, greater total sleep time and sleep efficiency, and right-side sleeping were each linked to better cognitive outcomes, whereas extended NREM stage 2, wakefulness, and supine sleeping were associated with poorer trajectories. Conclusions Twelve months of CPAP use was associated with attenuated cognitive decline and domain-specific gains in AD-related MCI with OSA. Sleep architecture and body position during sleep predicted cognitive outcomes, underscoring the therapeutic relevance of optimizing breathing and sleep quality. Larger, longer-term trials are warranted to confirm CPAP’s disease-modifying potential and to clarify the mechanistic role of sleep in AD progression.
- 18 July 2025
- Published by MDPI AG in Preprints.org
Open AccessThe Effect of CPAP Intervention on Sleep Architecture and Cognition in Alzheimer’s Disease Patients with Obstructive Sleep Apnea
Background Obstructive sleep apnea (OSA) is highly prevalent in the early stages of Alzheimer’s disease (AD), and its hallmark, sleep fragmentation, may accelerate cognitive decline. Continuous positive airway pressure (CPAP) improves OSA-related hypoxia during slow-wave sleep, but its cognitive benefits in AD remain unclear. Methods We performed a 12-month sub-analysis of a prospective, longitudinal pilot study that enrolled 21 adults (median age = 77 yr; 71% women) with MCI with AD confirmed biomarkers and polysomnography-diagnosed OSA. All participants underwent baseline overnight PSG and neuropsychological testing (CDR, MMSE, RBANS) that were repeated after 12 months. Twelve participants were CPAP-compliant (moderate/severe OSA) and nine were non-users (mild OSA/intolerance). Cognitive change scores (Δ = 12 months – baseline) were compared with generalized linear models adjusted for baseline cognition and apnea-hypopnea index; associations between baseline sleep parameters and cognitive trajectories were examined. And the association of sleep variables with the use of CPAP was also evaluated. Results Compared with non-users, CPAP users showed significantly slower global decline (Δ MMSE: p = 1.60e-02) and improvements in overall cognition (Δ RBANS Total: p = 2.80e-02), and RBANS subdomains (Δ RBANS FC: p = 1.06e-02; Δ RBANS SF: p = 4.53e-02). Longer baseline NREM stage 3 and REM sleep, greater total sleep time and sleep efficiency, and right-side sleeping were each linked to better cognitive outcomes, whereas extended NREM stage 2, wakefulness, and supine sleeping were associated with poorer trajectories. Conclusions Twelve months of CPAP use was associated with attenuated cognitive decline and domain-specific gains in AD-related MCI with OSA. Sleep architecture and body position during sleep predicted cognitive outcomes, underscoring the therapeutic relevance of optimizing breathing and sleep quality. Larger, longer-term trials are warranted to confirm CPAP’s disease-modifying potential and to clarify the mechanistic role of sleep in AD progression.
- Open Access
- 23 April 2025
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 11 (1) , 1-10
Clinical and brain volumetric correlates of decreased DTI-ALPS, suggestive of local glymphatic dysfunction, in iRBD
Glymphatic alterations may underlie neurodegeneration in alpha-synucleinopathies. Reduced Diffusion-Tensor Imaging ALong the Perivascular Space (DTI-ALPS), a proxy of perivascular glymphatic activity, has been scarcely studied in isolated REM sleep behaviour disorder (iRBD), a prodromal synucleinopathy stage. Furthermore, its associations with clinical symptoms and brain structural abnormalities remain unexplored. We assessed the DTI-ALPS in sixty-two patients with iRBD and twenty-three healthy controls (HC), exploring its associations with clinical symptoms, cortical thickness and brain volumetric data. iRBD patients exhibited a lower DTI-ALPS and poorer odor identification, semantic fluency and processing speed relative to HC. The DTI-ALPS positively correlated with cognitive performance, olfactory function and amygdalar, hippocampal, brainstem and diencephalic volumes, and negatively with age in iRBD. Perivascular glymphatic activity is compromised in iRBD and is associated with brain atrophy and clinical risk factors of progression to alpha-synucleinopathies, supporting the potential of the DTI-ALPS index as an early imaging neurodegeneration marker.
- 23 April 2025
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 11 (1) , 1-10
Open AccessClinical and brain volumetric correlates of decreased DTI-ALPS, suggestive of local glymphatic dysfunction, in iRBD
Glymphatic alterations may underlie neurodegeneration in alpha-synucleinopathies. Reduced Diffusion-Tensor Imaging ALong the Perivascular Space (DTI-ALPS), a proxy of perivascular glymphatic activity, has been scarcely studied in isolated REM sleep behaviour disorder (iRBD), a prodromal synucleinopathy stage. Furthermore, its associations with clinical symptoms and brain structural abnormalities remain unexplored. We assessed the DTI-ALPS in sixty-two patients with iRBD and twenty-three healthy controls (HC), exploring its associations with clinical symptoms, cortical thickness and brain volumetric data. iRBD patients exhibited a lower DTI-ALPS and poorer odor identification, semantic fluency and processing speed relative to HC. The DTI-ALPS positively correlated with cognitive performance, olfactory function and amygdalar, hippocampal, brainstem and diencephalic volumes, and negatively with age in iRBD. Perivascular glymphatic activity is compromised in iRBD and is associated with brain atrophy and clinical risk factors of progression to alpha-synucleinopathies, supporting the potential of the DTI-ALPS index as an early imaging neurodegeneration marker.
- Open Access
- 13 March 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (6) , 719
Olfactory Dysfunction as a Clinical Marker of Early Glymphatic Failure in Neurodegenerative Diseases
An abnormal accumulation of misfolded proteins is a common feature shared by most neurodegenerative disorders. Olfactory dysfunction (OD) is common in the elderly population and is present in 90% of patients with Alzheimer’s or Parkinson’s disease, usually preceding the cognitive and motor symptoms onset by several years. Early Aβ, tau, and α-synuclein protein aggregates deposit in brain structures involved in odor processing (olfactory bulb and tract, piriform cortex, amygdala, entorhinal cortex, and hippocampus) and seem to underly OD. The glymphatic system is a glial-associated fluid transport system that facilitates the movement of brain fluids and removes brain waste during specific sleep stages. Notably, the glymphatic system became less functional in aging and it is impaired in several conditions, including neurodegenerative diseases. As the nasal pathway has been recently described as the main outflow exit of cerebrospinal fluid and solutes, we hypothesized that OD may indeed be a clinical marker of early glymphatic dysfunction through abnormal accumulation of pathological proteins in olfactory structures. This effect may be more pronounced in peri- and postmenopausal women due to the well-documented impact of estrogen loss on the locus coeruleus, which may disrupt multiple mechanisms involved in glymphatic clearance. If this hypothesis is confirmed, olfactory dysfunction might be considered as a clinical proxy of glymphatic failure in neurodegenerative diseases.
- 13 March 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (6) , 719
Open AccessOlfactory Dysfunction as a Clinical Marker of Early Glymphatic Failure in Neurodegenerative Diseases
An abnormal accumulation of misfolded proteins is a common feature shared by most neurodegenerative disorders. Olfactory dysfunction (OD) is common in the elderly population and is present in 90% of patients with Alzheimer’s or Parkinson’s disease, usually preceding the cognitive and motor symptoms onset by several years. Early Aβ, tau, and α-synuclein protein aggregates deposit in brain structures involved in odor processing (olfactory bulb and tract, piriform cortex, amygdala, entorhinal cortex, and hippocampus) and seem to underly OD. The glymphatic system is a glial-associated fluid transport system that facilitates the movement of brain fluids and removes brain waste during specific sleep stages. Notably, the glymphatic system became less functional in aging and it is impaired in several conditions, including neurodegenerative diseases. As the nasal pathway has been recently described as the main outflow exit of cerebrospinal fluid and solutes, we hypothesized that OD may indeed be a clinical marker of early glymphatic dysfunction through abnormal accumulation of pathological proteins in olfactory structures. This effect may be more pronounced in peri- and postmenopausal women due to the well-documented impact of estrogen loss on the locus coeruleus, which may disrupt multiple mechanisms involved in glymphatic clearance. If this hypothesis is confirmed, olfactory dysfunction might be considered as a clinical proxy of glymphatic failure in neurodegenerative diseases.
- Open Access
Abnormal sleep blood pressure patterns are associated with diffusion tensor imaging along perivascular spaces index in cognitively impaired individuals
Blood pressure (BP) physiologically dips during sleep, and lack of dipping associates with adverse health outcomes and cognitive decline. Vascular pulsatility is the main driver of glymphatic cerebrospinal fluid transport, which removes metabolic waste products from the brain during sleep. We hypothesized that abnormal sleep BP patterns may affect glymphatic system health, and that this relationship may result in lower diffusion tensor imaging along perivascular spaces (DTI-ALPS) indices, a proposed neuroimaging index of glymphatic health. Twenty-one participants with mild-to-moderate cognitive impairment underwent 24-hour ambulatory BP monitoring, DTI-MRI and Alzheimer’s disease (AD) biomarker studies. Eight participants were classified as dippers (≥10%) and 13 as non-dippers (<10%), using sleep/awake systolic BP percentage of change. We found that non-dippers had lower DTI-ALPS even when adjusted by age and clinical stage (p=0.013). Stiffness measures (pulse wave velocity) were negatively correlated to DTI-ALPS (r=-0.5), but the association disappeared when adjusted by age. Positive AD biomarkers were more frequent in individuals who were classified as non-dippers of both systolic and diastolic BP, as compared to systolic and diastolic dippers (p=0.041). Our findings suggest that deviations of the physiological dipping sleep BP pattern may relate to poorer glymphatic function and increased AD pathology.
Open AccessAbnormal sleep blood pressure patterns are associated with diffusion tensor imaging along perivascular spaces index in cognitively impaired individuals
Blood pressure (BP) physiologically dips during sleep, and lack of dipping associates with adverse health outcomes and cognitive decline. Vascular pulsatility is the main driver of glymphatic cerebrospinal fluid transport, which removes metabolic waste products from the brain during sleep. We hypothesized that abnormal sleep BP patterns may affect glymphatic system health, and that this relationship may result in lower diffusion tensor imaging along perivascular spaces (DTI-ALPS) indices, a proposed neuroimaging index of glymphatic health. Twenty-one participants with mild-to-moderate cognitive impairment underwent 24-hour ambulatory BP monitoring, DTI-MRI and Alzheimer’s disease (AD) biomarker studies. Eight participants were classified as dippers (≥10%) and 13 as non-dippers (<10%), using sleep/awake systolic BP percentage of change. We found that non-dippers had lower DTI-ALPS even when adjusted by age and clinical stage (p=0.013). Stiffness measures (pulse wave velocity) were negatively correlated to DTI-ALPS (r=-0.5), but the association disappeared when adjusted by age. Positive AD biomarkers were more frequent in individuals who were classified as non-dippers of both systolic and diastolic BP, as compared to systolic and diastolic dippers (p=0.041). Our findings suggest that deviations of the physiological dipping sleep BP pattern may relate to poorer glymphatic function and increased AD pathology.
- Open Access
- 12 February 2025
- Published by MDPI AG in Preprints.org
Olfactory Dysfunction as a Clinical Marker of Early Glymphatic Dysfunction in Neurodegenerative Diseases
An abnormal accumulation of misfolded proteins is a common feature shared by most neurodegenerative disorders. Olfactory dysfunction (OD) is common in elderly population and is present in 90% of patients with Alzheimer’s or Parkinson’s disease, usually preceding the cognitive and motor symptoms onset by several years. Early Aβ, tau and α-synuclein protein aggregates have been observed in brain structures involved in odor processing (olfactory bulb and tract, piriform cortex, amygdala, entorhinal cortex, and hippocampus) and seem to underly OD. Glymphatic system is a glial-associated fluid transport system that facilitates the movement of CSF and ISF and removes brain waste during specific brain waste sleep stages. Noteworthy, glymphatic system became less functional in aging and is impaired in several conditions, including neurodegenerative diseases. As the nasal pathway has been recently described as the main outflow pathway of cerebrospinal fluid and solutes, we hypothesized that OD may be indeed a clinical marker of early glymphatic dysfunction that entails abnormal accumulation of pathological proteins in olfactory structures. Here we review the physiological, anatomical, and chronological evidence supporting this suggestion. If this hypothesis is confirmed, olfactory dysfunction could be considered as a clinical proxy of glymphatic dysfunction in neurodegenerative diseases.
- 12 February 2025
- Published by MDPI AG in Preprints.org
Open AccessOlfactory Dysfunction as a Clinical Marker of Early Glymphatic Dysfunction in Neurodegenerative Diseases
An abnormal accumulation of misfolded proteins is a common feature shared by most neurodegenerative disorders. Olfactory dysfunction (OD) is common in elderly population and is present in 90% of patients with Alzheimer’s or Parkinson’s disease, usually preceding the cognitive and motor symptoms onset by several years. Early Aβ, tau and α-synuclein protein aggregates have been observed in brain structures involved in odor processing (olfactory bulb and tract, piriform cortex, amygdala, entorhinal cortex, and hippocampus) and seem to underly OD. Glymphatic system is a glial-associated fluid transport system that facilitates the movement of CSF and ISF and removes brain waste during specific brain waste sleep stages. Noteworthy, glymphatic system became less functional in aging and is impaired in several conditions, including neurodegenerative diseases. As the nasal pathway has been recently described as the main outflow pathway of cerebrospinal fluid and solutes, we hypothesized that OD may be indeed a clinical marker of early glymphatic dysfunction that entails abnormal accumulation of pathological proteins in olfactory structures. Here we review the physiological, anatomical, and chronological evidence supporting this suggestion. If this hypothesis is confirmed, olfactory dysfunction could be considered as a clinical proxy of glymphatic dysfunction in neurodegenerative diseases.